Mats Lundgren

Mats Lundgren is a seasoned professional in the biopharmaceutical and vaccine sectors, currently serving as Vice President of Research and Development and Chief Scientific Officer at Abera Bioscience AB since May 2022. With a strong advisory role as a Senior Consultant at Phase2Phase Biopharma Consulting since July 2021, Mats provides strategic insights into biopharmaceutical processes. Previous experience includes roles at Cytiva and GE Healthcare as Customer Applications Director, where support was offered to global biopharma companies on bioprocessing technologies. Mats held a Team Manager position at AstraZeneca, overseeing bioprocess R&D for monoclonal antibodies, and served as Vice President of Bioprocessing and Production at Resistentia, focusing on therapeutic vaccines. Early career endeavors included a senior post-doctoral research associate role at Imperial College London, aimed at enhancing theoretical knowledge in gene regulation, and a scientist position at Pharmacia and Upjohn, specializing in biopharmaceutical production processes. Mats holds a Doctor of Philosophy (Ph.D.) in Immunology, Cell and Molecular Biology from Karolinska Institutet.